FDA warns of potential drug interaction between remdesivir, hydroxychloroquine
The Food and Drug Administration yesterday said chloroquine phosphate and hydroxychloroquine sulfate could reduce remdesivir's antiviral activity.
As a result, FDA, citing a non-clinical lab study, does not recommend co-administration of the drugs. The agency yesterday revoked emergency use authorizations for chloroquine and hydroxychloroquine for COVID-19 treatment.
Related News Articles
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…